Old Web
English
Sign In
Acemap
>
authorDetail
>
Sang Y. Huh
Sang Y. Huh
Bevacizumab
Phases of clinical research
Pathology
Medicine
Prospective cohort study
3
Papers
5
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Adjuvant carboplatin, docetaxel, bevacizumab, and erlotinib versus chemotherapy alone in patients with resected non-small cell lung cancer: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
2017
Journal of Clinical Oncology
David Waterhouse
John D. Hainsworth
F. A. Greco
Edward K. Barnes
Christopher F. Lobo
Victor G. Gian
Mathew John Joseph
James D. Peyton
Sang Y. Huh
D. Daniel
Raven Quinn
Howard A. Burris
David R. Spigel
Show All
Source
Cite
Save
Citations (1)
MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC).
2017
Journal of Clinical Oncology
Sachdev P. Thomas
Suprith Badarinath
Richard H. Greenberg
Sang Y. Huh
Kulumani M Sivarajan
Shibao Feng
Stefan J. Scherer
Christine Litz Curry
Christiane Langer
Heinz-Josef Lenz
Show All
Source
Cite
Save
Citations (4)
Biomarker distribution and characteristics for the first 100 patients in MAVERICC, a randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV in previously untreated metastatic colorectal cancer (mCRC).
2013
Journal of Clinical Oncology
Alexander Starodub
Sachdev P. Thomas
Fa-Chyi Lee
Vallathucherry Harish
Han A. Koh
Edith P. Mitchell
Romeo Ang Mandanas
Sang Y. Huh
Suprith Badarinath
Angelique Mittan
Larry Leon
Tobias Vogt
Christiane Langer
Heinz-Josef Lenz
Show All
Source
Cite
Save
Citations (0)
1